Link di approfondimento


  • Rotiroti, M., Buracchi, C., Arcangeli, S., Galimberti, S., Valsecchi, M., Perriello, V., et al. (2020). Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. MOLECULAR THERAPY, 28(9), 1974-1986. Dettaglio
  • Magnani, C., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., et al. (2020). Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. THE JOURNAL OF CLINICAL INVESTIGATION, 130(11), 6021-6033. Dettaglio
  • Introna, M., Lussana, F., Algarotti, A., Gotti, E., Valgardsdottir, R., Micò, C., et al. (2017). Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(12), 2070-2078. Dettaglio
  • Gaipa, G., Introna, M., Golay, J., Nolli, M., Vallanti, G., Parati, E., et al. (2016). Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. CYTOTHERAPY, 18(4), 481-486. Dettaglio
  • Casolaro, A., Golay, J., Albanese, C., Ceruti, R., Patton, V., Cribioli, S., et al. (2013). The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLOS ONE, 8(3). Dettaglio